A randomized, double‐blind, placebo‐controlled, dose‐escalation first‐in‐man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis

    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.

Related Topics

    loading  Loading Related Articles